DDInter1926 DDInter1676
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries. Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax. Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells. A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Venetoclax {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Venetoclax {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secobarbital
Venetoclax {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Venetoclax {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Venetoclax {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Venetoclax may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Venetoclax may lead to a major life threatening interaction when taken with Atazanavir
Venetoclax may lead to a major life threatening interaction when taken with Lorlatinib